Latest Articlesddd
The FDA Grants Fast Track Status to DelMar Pharmaceuticals’ Product VAL-083 Dec.26, 2017 – DelMar Pharmaceuticals (DMPI) announced …
Two months ahead of the PDUFA date scheduled for February 28, 2018, the Food and Drug …
Based on statistically significant results from the randomized phase 2 CABOSUN trial in patients with previously …
After years of spending efforts in creating and developing its pipeline products, Portola (PTLA) has just been granted …
UCART19 UCART19 is one of the Cellectis’ (CLLS) lead allogeneic anti-CD19 CAR T-cell products. The word allogeneic is important as it makes …
Juno Therapeutics (JUNO) is one of the casualties that occurred during the 59th American Society of Hematology (ASH) Annual …
The Week in Review #13 From the Prohost Portfolio - 1. Betting on the technology - …
Gilead Sciences (GILD) has unsurprisingly agreed to acquire Cell Design Labs in a structured buy out …
All the necessities, including future plans, are being taken care of by institutions, academia and biotech …
Prohost Letter #415 New Promising Technologies PROTAC - A Technology That Offers a Superior Class of …
The Week in Review #12 Answering You - Many questions still need answers in the biotech’s …
On Nov. 21, 2017, Portola Pharmaceuticals (PTLA) announced that the U.S. Food and Drug Administration (FDA) has informed …
DelMar Pharmaceuticals (DMPI) -- A biopharmaceutical company focused on the development of cancer therapies provided an overview …
The Treatment is Not A New Way as Being Stated, It is Only the Target, Which …
The Week in Review #11 A New Era - Faster than the speed of light, the management …
Important news has come from the FDA, which issued new guidelines to speed the introduction of …
Yes, it is Sangamo’s (SGMO) zinc finger nuclease (ZFN) gene-editing technology, which for the first time …
Halozyme Therapeutics (HALO) announced that it will present nonclinical data at the 32nd Annual Meeting of the Society …
A couple of days ago, Cellectis (CLLS), which uses its own proprietary gene editing technology known …
Nektar Therapeutics (NKTR) stock rallied, reaching all-time high with positive results in every aspect of the firm’s …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
